Skip to content
Vincristine
Marqibo, Oncovin, Vincasar, Vincrex (vincristine) is a small molecule pharmaceutical. Vincristine was first approved as Oncovin on 1982-01-01. It is used to treat hodgkin disease, leukemia, neuroblastoma, non-hodgkin lymphoma, and rhabdomyosarcoma amongst others in the USA. The pharmaceutical is active against tubulin beta chain.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
urogenital diseasesD000091642
hemic and lymphatic diseasesD006425
hereditary congenital and neonatal diseases and abnormalitiesD009358
immune system diseasesD007154
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vincristine sulfate
Tradename
Company
Number
Date
Products
MARQIBO KITAcrotech BiopharmaN-202497 DISCN2012-08-09
1 products, RLD
ONCOVINEli LillyN-014103 DISCN1982-01-01
3 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
vincasar pfsANDA2020-09-30
vincristine sulfateANDA2023-02-03
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hodgkin disease—D006689C81
leukemia—D007938C95
neuroblastomaEFO_0000621D009447—
non-hodgkin lymphoma—D008228C85.9
rhabdomyosarcoma—D012208—
wilms tumorEFO_0000212D009396—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01C: Plant alkaloids and other natural products, antineoplastic drugs
— L01CA: Vinca alkaloids and analogues, antineoplastic
— L01CA02: Vincristine
HCPCS
Code
Description
J9370
Vincristine sulfate, 1 mg
J9371
Injection, vincristine sulfate liposome, 1 mg
Clinical
Clinical Trials
154 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223C85.9114121432
Non-small-cell lung carcinomaD002289———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hodgkin diseaseD006689C8152511—139
Urinary bladder neoplasmsD001749C67—116——16
Lung neoplasmsD008175C34.90216——9
MelanomaD008545243——8
Prostatic neoplasmsD011471C61—13——4
Urethral neoplasmsD014523EFO_0003846—23——4
GliomaD005910EFO_0000520—31——4
Langerhans-cell histiocytosisD006646C96.6—12—13
Skin neoplasmsD012878EFO_0004198C44—11——2
Transitional cell carcinomaD002295—11——2
Show 7 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B2013———3
NeoplasmsD009369C8021———2
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.0—2———2
Invasive hydatidiform moleD002820D39.2—2———2
Neurofibromatosis 1D009456Q85.0111———2
Kidney neoplasmsD007680EFO_0003865C6411———2
Renal cell carcinomaD002292—1———1
SarcomaD012509—1———1
Kaposi sarcomaD012514C46—1———1
Ureteral neoplasmsD014516EFO_0003844C66—1———1
Show 3 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Central nervous system neoplasmsD0165432————2
Neoplasm metastasisD009362EFO_00097081————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-hodgkin lymphomaD008228C85.9————11
Ataxia telangiectasiaD001260Orphanet_100G11.3————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVINCRISTINE
INNvincristine
Description
Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine.
Classification
Small molecule
Drug classvinca alkaloids
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Identifiers
PDB—
CAS-ID57-22-7
RxCUI11202
ChEMBL IDCHEMBL90555
ChEBI ID28445
PubChem CID5978
DrugBankDB00541
UNII ID5J49Q6B70F (ChemIDplus, GSRS)
Target
Agency Approved
TUBB
TUBB
Organism
Homo sapiens
Gene name
TUBB
Gene synonyms
TUBB5
NCBI Gene ID
203068
Protein name
tubulin beta chain
Protein synonyms
beta Ib tubulin, epididymis secretory sperm binding protein, tubulin beta-1 chain, Tubulin beta-5 chain, tubulin, beta polypeptide
Uniprot ID
P07437
Mouse ortholog
Tubb5 (22154)
tubulin beta-5 chain (Q3UF52)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Marqibo - Spectrum Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 50,829 documents
View more details
Safety
Black-box Warning
Black-box warning for: Vincasar pfs, Vincristine sulfate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
4,822 adverse events reported
View more details